Literature DB >> 24352508

The proportion of lymphocytic inflammation with CD123-positive cells in lupus erythematous profundus predict a clinical response to treatment.

Azusa Miyashita1, Satoshi Fukushima, Takamitsu Makino, Yuichiro Yoshino, Junji Yamashita, Noritoshi Honda, Jun Aoi, Asako Ichihara, Masatoshi Jinnin, Yuji Inoue, Hironobu Ihn.   

Abstract

Lupus erythematosus profundus is a rare inflammatory disorder of subcutaneous fat in patients with lupus ery-thematosus. Previous reports suggested that plasmacytoid dendritic cells, which expressed CD123 and CD303 antigens, play a central proinflammatory role in the patho-genesis of lupus erythematosus. To find the factors that determine the response to treatment, we analysed 23 skin specimens from the patients with lupus erythematosus profundus. The patients with considerable lymphocytic inflammation with high percentages of CD123+ cells in dermis and subcutaneous fat significantly responded to the systemic corticosteroid therapies. On the other hand, the patients with minor lymphocytic inflammation with low percentages of CD123+ cells showed poor response to treatments. The mean percentage of CD123+ cells in patients who showed good response to therapy was significantly higher than those that showed poor response (p = 0.027). These results suggest that the clinical response to treatment of lupus erythematosus profundus could be predicted from the histological features.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24352508     DOI: 10.2340/00015555-1777

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Value of CD123 Immunohistochemistry and Elastic Staining in Differentiating Discoid Lupus Erythematosus from Lichen Planopilaris.

Authors:  Fatemeh Sari Aslani; Mozhdeh Sepaskhah; Zahra Bagheri; Mojgan Akbarzadeh-Jahromi
Journal:  Int J Trichology       Date:  2020-05-05

2.  A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus.

Authors:  Shereen Oon; Huy Huynh; Tsin Yee Tai; Milica Ng; Katherine Monaghan; Mark Biondo; Gino Vairo; Eugene Maraskovsky; Andrew D Nash; Ian P Wicks; Nicholas J Wilson
Journal:  JCI Insight       Date:  2016-05-05

Review 3.  Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Authors:  Shereen Oon; Nicholas J Wilson; Ian Wicks
Journal:  Clin Transl Immunology       Date:  2016-05-13

4.  CD123 immunoexpression in cutaneous lupus erythematosus, polymorphous light eruption, pityriasis rosea, and mycosis fungoides.

Authors:  Ebru Karagun; Mehmet Gamsizkan; Seyma Buyucek; Sinem Coskun
Journal:  Postepy Dermatol Alergol       Date:  2022-01-07       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.